Diabetic macular edema: new trends in management

References

• Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv. Ophthalmol.54, 1–32 (2009).
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology102, 7–16 (1995).
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ317, 703–713 (1998).
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch. Ophthalmol.103(12), 1796–1806 (1985).
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology98(5), 766–785 (1991).
   PubMed Web of Science ®Google Scholar
• Wallow IH. Repair of the pigment epithelial barrier following photocoagulation. Arch. Ophthalmol.102, 126–135 (1984).
   PubMedGoogle Scholar
• Marshall J, Clover G, Rothery S. Some new findings on retinal irradiation by krypton and argon lasers. Doc. Ophthalmol. Proc. Ser.36, 21–27 (1984).
   Google Scholar
• Stefansson E, Machemer R, de Juan E Jr et al. Retinal oxygenation and laser treatment in patients with diabetic retinopathy. Am. J. Ophthalmol.113, 36–38 (1992).
   PubMed Web of Science ®Google Scholar
• Yu DY, Cringle SJ, Su E, Yu PK, Humayun MS, Dorin G. Laser-induced changes in intraretinal oxygen distribution in pigmented rabbits. Invest. Ophthalmol. Vis. Sci.46, 988–999 (2005).
   PubMedGoogle Scholar
• Ferris F. Early photocoagulation in patients with either Type 1 or Type 2 diabetes. Trans. Am. Ophthalmol. Soc.94, 505–537 (1996).
   PubMedGoogle Scholar
• Meyer CH. Current treatment approaches in diabetic macular edema. Ophthalmologica221, 118–131(2007).
   PubMed Web of Science ®Google Scholar
• Schatz H, Madeira D, McDonald HR et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch. Ophthalmol.109, 1549–1551 (1991).
   PubMedGoogle Scholar
• Morgan CM, Schatz H. Atrophic creep of the retinal pigment epithelium after focal macular photocoagulation. Ophthalmology96, 96–103 (1998).
   Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no 19. Arch. Ophthalmol.113, 1144–1155 (1995).
   PubMed Web of Science ®Google Scholar
• Lewen RM. Subretinal neovascularization complicating laser photocoagulation of diabetic maculopathy. Ophthalmic. Surg.19, 734–737 (1988).
   PubMedGoogle Scholar
• Lewis H, Schachat AP, Haimann MH et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology97, 503–510; discussion 510–511 (1990).
   PubMed Web of Science ®Google Scholar
• Guyer DR, D’Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am. J. Ophthalmol.113, 652–656 (1992).
   PubMed Web of Science ®Google Scholar
• Rutledge BK, Wallow IH, Poulsen GL. Sub-pigment epithelial membranes after photocoagulation for diabetic macular edema. Arch. Ophthalmol.111, 608–613 (1993).
   PubMedGoogle Scholar
• Striph GG, Hart WM Jr, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology95, 1673–1679 (1988).
   PubMed Web of Science ®Google Scholar
• Hudson C, Flanagan JG, Turner GS et al. Influence of laser photocoagulation for clinically significant diabetic macular oedema (DMO) on short-wavelength and conventional automated perimetry. Diabetologia41, 1283–1292 (1998).
   PubMed Web of Science ®Google Scholar
• Ishiko S, Ogasawara H, Yoshida A et al. The use of scanning laser ophthalmoscope microperimetry to detect visual impairment caused by macular photocoagulation. Ophthalmic. Surg. Lasers29, 95–98 (1998).
   PubMedGoogle Scholar
• Okuyama M, Okisaka S. Automatic static threshold perimetry is useful for estimating the effects of laser photocoagulation on diabetic maculopathy. Ophthalmic. Res.30, 207–215 (1998).
   PubMed Web of Science ®Google Scholar
• Roider J. Laser treatment of retinal diseases by subthreshold laser effects. Semin. Ophthalmol.14, 19–26 (1999).
   PubMedGoogle Scholar
• Friberg TR. Subthreshold (invisible) modified grid diode laser photocoagulation and diffuse diabetic macular edema (DDME). Ophthalmic. Surg. Lasers30, 705 (1999).
   PubMedGoogle Scholar
• Stanga PE, Reck AC, Hamilton AMP. Micropulse laser in the treatment of diabetic macular edema. Semin. Ophthalmol.14, 210–213 (1999).
   PubMedGoogle Scholar
• Fong DS, Strauber SF, Aiello LP et al.; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch. Ophthalmol.125, 469–480 (2007).
   PubMedGoogle Scholar
• Martidis A, Duker JS, Greenberg PB et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology109, 920–927 (2002).
   PubMed Web of Science ®Google Scholar
• Massin P, Audren F, Haouchine B et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology111, 218–225 (2004).
   PubMed Web of Science ®Google Scholar
• Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology111, 2044–2049 (2004).
   PubMed Web of Science ®Google Scholar
• Karaçorlu M, Özdemir H, Karaçorlu S et al. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye19, 382–386 (2005).
   PubMed Web of Science ®Google Scholar
• Lang Y, Leibu R, Shoham N et al. Evaluation of intravitreal Kenalog toxicity in humans. Ophthalmology114, 724–731 (2007).
   PubMed Web of Science ®Google Scholar
• Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in muller cells under continuous cobalt stimulation. Invest. Ophthalmol. Vis. Sci.46, 4336–4341 (2005).
   PubMed Web of Science ®Google Scholar
• Gardner TW, Antonetti DA, Barber AJ et al.; Penn State Retina Research Group. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol.47(Suppl.), S253–S262 (2002).
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology115, 1447–1459 (2008).
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW et al. Diabetic retinopathy clinical research network, randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology117, 1064–1077 (2010).
   PubMed Web of Science ®Google Scholar
• Hauser D, Bukelman A, Pokroy R et al. Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4mg . Retina28, 825–830 (2008).
   PubMed Web of Science ®Google Scholar
• Audren F, Lecleire-Collet A, Erginay A et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: Phase 2 trial comparing 4mg versus 2mg . Am. J. Ophthalmol.142, 794–799 (2006).
   PubMed Web of Science ®Google Scholar
• Lam DS, Chan CK, Mohamed S et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br. J. Ophthalmol.91, 199–203 (2007).
   PubMed Web of Science ®Google Scholar
• Gillies MC, Islam FM, Larsson J et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clin. Experiment. Ophthalmol.38, 605–612 (2010).
   PubMed Web of Science ®Google Scholar
• Quiram PA, Gonzales CR, Schwartz SD. Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol.141(3), 580–582 (2006).
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Billson FA et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch. Ophthalmol.122(3), 336–340 (2004).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med.331, 1480–1487 (1994).
   PubMed Web of Science ®Google Scholar
• Derevjanik NL, Vinores SA, Xiao WH et al. Quantitative assessment of the integrity of the blood–retinal barrier in mice. Invest. Ophthalmol. Vis. Sci.43, 2462–2467 (2002).
   PubMed Web of Science ®Google Scholar
• Ozaki H, Hayashi H, Vinores SA et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood–retinal barrier in rabbits and primates. Exp. Eye Res.64, 505–517 (1997).
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr, Adamis AP, Altaweel M et al. Macugen diabetic retinopathy study group. A Phase 2 randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology112(10), 1747–1757 (2005).
   PubMed Web of Science ®Google Scholar
• Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS. Macugen 1013 study group. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology118(6), 1107–1118 (2011).
   PubMed Web of Science ®Google Scholar
• Chung EJ, Roh MI, Kwon OW, Koh HJ. Effects of macular ischemia on the outcome of intravitrealbevacizumab therapy for diabetic macular edema. Retina28, 957–963 (2008).
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Sanchez JG, Wu L et al. Pan-American collaborative retina study group (PACORES). Primary intravitrealbevacizumab for diffuse diabetic macular edema: the Pan-American collaborative retina study group at 24 months. Ophthalmology116, 1488–1497 (2009).
   PubMed Web of Science ®Google Scholar
• Haritoglou C, Kook D, Neubauer A et al. Intravitrealbevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina26, 999–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Kook D, Wolf A, Kreutzer T et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina28, 1053–1060 (2008).
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Bijanzadeh B et al. Intravitrealbevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina27, 1187–1195 (2007).
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology116, 1142–1150 (2009).
   PubMed Web of Science ®Google Scholar
• Michaelides et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12 months data: report 2. Ophthalmology117, 1078–1086 (2010).
   PubMed Web of Science ®Google Scholar
• Scott IU, Edwards AR, Beck RW et al. Diabetic retinopathy clinical research network. A Phase 2 randomized clinical trial of intravitrealbevacizumab for diabetic macular edema. Ophthalmology114(10), 1860–1867 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355, 1419–1431 (2007).
   Google Scholar
• Massin P, Bandello F, Garweg J et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, doublemasked, multicenter Phase 2 study. Diabet. Care33, 2399–2405 (2010).
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Heier JS et al. READ-2 study group. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology116, 2175–2181 (2009).
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW et al. Diabetic retinopathy clinical research network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology117, 1064–1077 (2010).
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U et al.; RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology118(4), 615–625 (2011).
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW et al. Diabetic retinopathy clinical research network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology117, 1064–1077 (2010).
   PubMed Web of Science ®Google Scholar
• Do DV, Schmidt-Erfurth U, Gonzalez VH et al. The DA VINCI study: Phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology118(9), 1819–1826 (2011).
   PubMed Web of Science ®Google Scholar
• Tolentino MG, Do D. One-year results of the Da Vinci study of VEGF trap-eye in DME. Presented at: The Association for Research in Vision and Ophthalmology-Visionary Genomics. Fort Lauderdale, FL, USA, 1–5 May 2011.
   Google Scholar
• Nasrallah FP, Jalkh AE, Van Coppenolle F et al. The role of the vitreous in diabetic macular edema. Ophthalmology95(10), 1335–1339 (1988).
   PubMed Web of Science ®Google Scholar
• Nasrallah FP, Van De Velde F, Jalkh AE et al. Importance of the vitreous in young diabetics with macular edema. Ophthalmology96, 1511–1516 (1989).
   PubMedGoogle Scholar
• Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes. Arch. Clin. Exp. Ophthalmol.242, 630–637 (2004).
   PubMed Web of Science ®Google Scholar
• Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars planavitrectomy of diffuse nontractional diabetic macular edema. Retina28, 420–426 (2008).
   PubMed Web of Science ®Google Scholar
• Foos RY, Kreiger AE, Forsythe AB, Zakka KA. Posterior vitreous detachment in diabetic subjects. Ophthalmology87, 122–128 (1980).
   PubMed Web of Science ®Google Scholar
• Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina20, 126–133 (2000).
   PubMed Web of Science ®Google Scholar
• Harbour JW, Smiddy WE, Flynn HW Jr, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am. J. Ophthalmol.121, 405–413 (1996).
   PubMed Web of Science ®Google Scholar
• Ikeda T, Sato K, Katano T, Hayashi Y. Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. Br. J. Ophthalmol.83, 12–14 (1999).
   PubMedGoogle Scholar
• Schepens CL, Avila MP, Jalkh AE, Trempe CL. Role of the vitreous in cystoid macular edema. Surv. Ophthalmol.28(Suppl.), S499–S504 (1984).
   PubMed Web of Science ®Google Scholar
• Hikichi T, Fugio N, Akiba J, Azuma Y, Tadabashi M, Yashida A. Association between the short term natural history of diabetic macular edema and the vitreomacular relationship in Type 2 diabetes mellitus. Ophthalmology104, 473–478 (1997).
   PubMed Web of Science ®Google Scholar
• Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology99(5), 753–759 (1992).
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Riemann CD, Sears JE, Lewis H. Macular traction detachment and diabetic macular edema associated with posterior hyaloidaltraction. Am. J. Ophthalmol.131(1), 44–49 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis H. The role of vitrectomy in the treatment of diabetic macular edema [comment]. Am. J. Ophthalmol.131(1), 123–125 (2001).
   PubMed Web of Science ®Google Scholar
• Shah SP, Patel M, Thomas D, Aldington S, Laidlaw DA. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. Br. J. Ophthalmol.90, 33–36 (2006).
   PubMed Web of Science ®Google Scholar
• Laidlaw DA. Vitrectomy for diabetic macular oedema. Eye22, 1337–1341 (2008).
   PubMed Web of Science ®Google Scholar
• Kishi S, Demaria C, Shimizu K. Vitreous cortex remnants at the fovea after spontaneous vitreous detachment. Int. Ophthalmol.9(4), 253–260 (1986).
   PubMed Web of Science ®Google Scholar
• Ikeda T, Sato K, Katano T, Hayashi Y. Improved visual acuity following pars planavitrectomy for diabetic cystoid macular edema and detached posterior hyaloid. Retina20, 220–222 (2000).
   PubMedGoogle Scholar
• La Heij EC, Hebdrikse F, Kessels AGH, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch. Clin. Exp. Ophthalmol.239(4), 264–270 (2001).
   PubMedGoogle Scholar
• Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv. Ophthalmol.51(4), 364–380 (2006).
   PubMed Web of Science ®Google Scholar
• Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol. Scand.79(5), 435–440 (2001).
   PubMedGoogle Scholar
• Stolba U, Binder S, Gruber D, Krebs I, Aggermann T, Neumaier B. Vitrectomy for persistent diffuse diabetic macular edema. Am. J. Ophthalmol.140(2), 295–301 (2005).
   PubMed Web of Science ®Google Scholar
• Kohno T, Sorgente N, Doodnight R, Ryan SJ. Alterations in the distribution of fibronectin and laminin in the diabetic human eye. Invest. Ophthalmol. Vis. Sci.28, 515–521 (1987).
   PubMedGoogle Scholar
• Ljubimov AV, Burgeson RE, Butkowski RJ et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J. Histochem. Cytochem.44, 1469–1479 (1996).
   PubMed Web of Science ®Google Scholar
• Matsunaga N, Ozeki H, Hirabayashi Y, Shimada S, Ogura Y. Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. Retina25, 311–316 (2005).
   PubMed Web of Science ®Google Scholar
• Bahadir M, Ertan A, Mertoglu O. Visual acuity comparison of vitrectomy with and without internal limiting membrane removal in the treatment of diabetic macular edema. Int. Ophthalmol.26, 3–8 (2005).
   PubMedGoogle Scholar
• Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars planavitrectomy with internal limiting membrane removal in diabetic macular edema. Retina27, 557–566 (2007).
   PubMed Web of Science ®Google Scholar
• Kamura Y, Sato Y, Isomae T, Shimada H. Effects of internal limiting membrane peeling in vitrectomy on diabetic cystoid macular edema patients. Jpn. J. Ophthalmol.49, 297–300 (2005).
   PubMedGoogle Scholar
• Ikagawa H, Yoneda M, Iwaki M et al. Chemical toxicity of indocyanine green damages retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci.46, 2531–2539 (2005).
   PubMedGoogle Scholar
• Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina28, 410–419 (2008).
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network Writing Committee on behalf of the DRCR.net; Haller JA, Qin H, Apte RS et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology117, 1087–1093 (2010).
   PubMed Web of Science ®Google Scholar
• Flaxel CJ, Edwards AR, Aiello LP et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema. Retina30, 1488–1495 (2010).
   PubMed Web of Science ®Google Scholar
• Pendergast SD. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. Curr. Opin. Ophthalmol.9, 71–75 (1998).
   PubMedGoogle Scholar
• Jaffe GJ, Ben-Nun J, Guo H et al. Fluocinoloneacetonide sustained drug delivery device to treat severe uveitis. Ophthalmology107, 2024–2033 (2000).
   PubMed Web of Science ®Google Scholar
• Driot JY, Novack GD, Rittenhouse KD et al. Ocular pharmacokinetics of fluocinoloneacetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J. Ocul. Pharmacol. Ther.20, 269–275 (2004).
   PubMed Web of Science ®Google Scholar
• Pearson P, Levy B, Comstock T. Fluocinolone acetonide implant study group. Fluocinoloneacetonideintravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinical trial [abstract]. Invest. Ophthalmol. Vis. Sci.47, (2006) (E-Abstract 5442).
   PubMedGoogle Scholar
• Campochiaro PA, Hafiz G, Shah SM et al. Famous study group. Sustained ocular delivery of fluocinoloneacetonide by an intravitreal insert. Ophthalmology117, 1393–1399 (2010).
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A et al. Long-term benefit of sustained-delivery fluocinoloneacetonide vitreous inserts for diabetic macular edema. Ophthalmology118, 626–635 (2011).
   PubMed Web of Science ®Google Scholar
• Haller JA, Kuppermann BD, Blumenkranz MS et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch. Ophthalmol.128(3), 289–296 (2010).
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S et al.; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina31(5), 915–923 (2011).
   PubMed Web of Science ®Google Scholar
• Dorin G. Subthreshold and micropulse diode laser photocoagulation. Semin. Ophthalmol.18(3), 147–153 (2003).
   PubMedGoogle Scholar
• Lanzetta P, Dorin G, Piracchio A et al. Theoretical bases of non-ophthalmoscopically visible endpoint photocoagulation. Semin. Ophthalmol.16(1), 8–11 (2001).
   PubMedGoogle Scholar
• Akduman L, Olk RJ. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthalmic Surg. Lasers30(9), 706–714 (1999).
   PubMedGoogle Scholar
• Figueira J, Khan J, Nunes S et al. Prospective randomized controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br. J. Ophthalmol.93(10), 1341–1344 (2009).
   PubMed Web of Science ®Google Scholar
• Ulbig MW, McHugh DA, Hamilton AM. Diode laser photocoagulation for diabetic macular oedema. Br. J. Ophthalmol.79(4), 318–321 (1995).
   PubMed Web of Science ®Google Scholar
• Ohkoshi K, Yamaguchi T. Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am. J. Ophthalmol.149(1), 133–139 (2010).
   PubMed Web of Science ®Google Scholar
• Venkatesh P, Ramanjulu R, Azad R, Vohra R, Garg S. Subthreshold micropulse diode laser and double frequency neodymium: YAG laser in treatment of diabetic macular edema: a prospective, randomized study using multifocal electroretinography. Photomed. Laser Surg.29(11), 727-733 (2011).
   PubMed Web of Science ®Google Scholar
• Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin. Ophthalmol.14, 223–232 (1999).
   PubMedGoogle Scholar
• Limb GA, Webster L, Soomro H, Janikoun S, Shilling J. Platelet expression of tumour necrosis factor-α (TNF-α), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin. Exp. Immunol.118, 213–218 (1999).
   PubMed Web of Science ®Google Scholar
• Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest. Ophthalmol. Vis. Sci.42, 1586–1591 (2001).
   PubMed Web of Science ®Google Scholar
• Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. Activation of nuclear factor-k B induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes51, 2241–2248 (2002).
   PubMed Web of Science ®Google Scholar
• Canete JD, Pablos JL, Sanmarti R et al. Antiangiogenic effects of anti-tumor necrosis factor α therapy with infliximab in psoriatic arthritis. Arthrit. Rheum.50, 1636–1641 (2004).
   PubMed Web of Science ®Google Scholar
• Simo R, Hernandez C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care32, 1556–1562 (2009).
   PubMed Web of Science ®Google Scholar
• Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin. Immunopathol.30, 65–84 (2008).
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Grigoropoulos V, Emfietzoglou I et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32 weeks study. Diabetes Care33(7), 1523–1528 (2010).
   PubMed Web of Science ®Google Scholar
• Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American collaborative retina study group. Retina31(2), 298–303 (2011).
   PubMed Web of Science ®Google Scholar
• Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J, Pujol O. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina30(10), 1601–1608 (2010).
   PubMed Web of Science ®Google Scholar
• Tsilimbaris MK, Panagiotoglou TD, Charisis SK, Anastasakis A, Krikonis TS, Christodoulakis E. The use of intravitreal etanercept in diabetic macular oedema. Semin. Ophthalmol.22(2), 75–79 (2007).
   PubMedGoogle Scholar
• Xu X, Qi Z, Xin X, Zhang S, Gu Q, Luo D. Blood–retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin induced diabetic rats. Curr. Eye Res.28, 251–256 (2004).
   PubMed Web of Science ®Google Scholar
• Suzuma K, Takahara N, Suzuma I. Characterization of protein kinase C β isoform’s action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc. Natl Acad. Sci. USA99, 721–726 (2002).
   PubMed Web of Science ®Google Scholar
• Zhu Q, Xu X, Xia X, Gu Q, Ho PC. Role of protein kinase C on the alteration of retinal endothelin-1 in streptozotocin induced diabetic rats. Exp. Eye Res.81, 200–206 (2005).
   PubMedGoogle Scholar
• PKC -DRS2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology113, 2221–2230 (2006).
   PubMed Web of Science ®Google Scholar
• The PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol.125(3), 318–324 (2007).
   PubMed Web of Science ®Google Scholar
• Stone CA, Torchiana ML, Navarro A, Beyer KH. Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine. J. Pharmaocol.117, 169–183 (1956).
   Google Scholar
• Kiuchi K, Matsuoka M, Wu JC et al. Mecamylamine suppresses basal and nicotine-stimulated choroidal neovascularization. Invest. Ophthalmol. Vis. Sci.49, 1705–1711 (2008).
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Shah SM, Hafiz G et al. Topical mecamylamine for diabetic macular edema. Am. J. Ophthalmol.149, 839–851 (2010).
   PubMed Web of Science ®Google Scholar
• Han DP, Abrams GW, Aaberg TM. Surgical excision of the attached posterior hyaloid. Arch. Ophthalmol.106, 998–1000 (1998).
   Google Scholar
• Vander JF, Kleiner R. A method for induction of posterior vitreous detachment during vitrectomy. Retina12, 172–173 (1992).
   PubMedGoogle Scholar
• Verstraeten TC, Chapman C, Hartzer M et al. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch. Ophthalmol.111, 849–854 (1993).
   PubMedGoogle Scholar
• Benz MS, Packo KH, Gonzalez V et al. A placebo-controlled trial of microplasminintravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology117(4), 791–797 (2010).
   PubMed Web of Science ®Google Scholar
• Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidalprodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation24(4), 371–384 (2000).
   PubMed Web of Science ®Google Scholar
• Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin. Ophthalmol.2(4), 689–692 (2008).
   PubMedGoogle Scholar
• Krishnadev N, Forooghian F, Cukras C et al. Subconjunctivalsirolimus in the treatment of diabetic macular edema. Graefes Arch. Clin. Exp. Ophthalmol.249(11), 1627–1633 (2011).
   PubMed Web of Science ®Google Scholar
• Fong DS, Segal PP, Myers F, Ferris FL, Hubbard LD, Davis MD. Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Arch. Ophthalmol.115, 873–877 (1997).
   PubMed Web of Science ®Google Scholar
• Takagi H, Otani A, Kiryu J, Ogura Y. New surgical approach for removing massive foveal hard exudates in diabeticmacular edema. Ophthalmology106, 249–257 (1999).
   PubMedGoogle Scholar
• Sakuraba T, Suzuki Y, Mizutani H, Nakazawa M. Visual improvement after removal of submacular exudates in patients with diabetic maculopathy. Ophthalmic Surg. Lasers31, 287–291 (2000).
   PubMedGoogle Scholar
• Takaya K, Suzuki Y, Mizutani H, Sakuraba T, Nakazawa M. Long-term results of vitrectomy for removal of submacular hard exudates in patients with diabetic maculopathy. Retina24(1), 23–29 (2004).
   PubMed Web of Science ®Google Scholar
• Freyler H. Peripheral fluorescence angiography in diabetic retinopathy. Klin. Monatsbl. Augenheilkd.186, 184–186 (1985).
   PubMed Web of Science ®Google Scholar
• Kimble JA, Brandt BM, McGwin G Jr. Clinical examination accurately locates capillary nonperfusion in diabetic retinopathy. Am. J. Ophthalmol.139, 555–557 (2005).
   PubMed Web of Science ®Google Scholar
• Suner I, Hammer M, Grizzard S. RaScaL study – results of a pilot study of combination peripheral scatter laser and ranibizumab for diabetic macular oedema associated with peripheral non-perfusion. Presented at: 11th Euroretina Congress. London, UK, 26–29 May 2011.
   Google Scholar